Kura Oncology had its Relative Strength (RS) Rating stock upgraded from 81 to 93 Thursday.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. This exclusive rating from Investor's Business Daily measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks typically have an RS Rating north of 80 as they launch their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Kura Oncology Stock A Buy?
Kura Oncology stock is still within a buying range after breaking past a 17.53 buy point in a consolidation. Once a stock moves 5% or higher beyond the original entry, it's considered out of buy range. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Regarding fundamentals, Kura Oncology stock has posted rising EPS growth over the last three quarters. Revenue growth has been a different story, coming in at 0% in the latest report.
Kura Oncology stock holds the No. 62 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals, Amphastar Pharmaceutcls and Corcept Therapeutics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
